BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27347876)

  • 1. Evolution of the Transmission-Blocking Vaccine Candidates Pvs28 and Pvs25 in Plasmodium vivax: Geographic Differentiation and Evidence of Positive Selection.
    Chaurio RA; Pacheco MA; Cornejo OE; Durrego E; Stanley CE; Castillo AI; Herrera S; Escalante AA
    PLoS Negl Trop Dis; 2016 Jun; 10(6):e0004786. PubMed ID: 27347876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic diversity and natural selection of transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 in Plasmodium vivax Myanmar isolates.
    Lê HG; Kang JM; Jun H; Lee J; Moe M; Thái TL; Lin K; Myint MK; Yoo WG; Sohn WM; Kim TS; Na BK
    Acta Trop; 2019 Oct; 198():105104. PubMed ID: 31336059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.
    Tsuboi T; Kaslow DC; Gozar MM; Tachibana M; Cao YM; Torii M
    Mol Med; 1998 Dec; 4(12):772-82. PubMed ID: 9990863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran.
    Zakeri S; Razavi S; Djadid ND
    Acta Trop; 2009 Mar; 109(3):176-80. PubMed ID: 18950597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic diversity of transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 in Plasmodium vivax isolates from China.
    Wang S; Tian P; Li S; Liu H; Guo X; Huang F
    BMC Infect Dis; 2022 Dec; 22(1):944. PubMed ID: 36527077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic diversity of transmission-blocking vaccine candidates Pvs25 and Pvs28 in Plasmodium vivax isolates from Yunnan Province, China.
    Feng H; Zheng L; Zhu X; Wang G; Pan Y; Li Y; Yang Y; Lin Y; Cui L; Cao Y
    Parasit Vectors; 2011 Nov; 4():224. PubMed ID: 22117620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of Plasmodium vivax ookinete (sexual stage) surface proteins (Pvs25 and Pvs28) from Thailand.
    Kuesap J; Suphakhonchuwong N; Rungsihirunrat K
    Infect Genet Evol; 2024 Mar; 118():105558. PubMed ID: 38244749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence variation of ookinete surface proteins Pvs25 and Pvs28 of Plasmodium vivax isolates from Southern Mexico and their association to local anophelines infectivity.
    González-Cerón L; Alvarado-Delgado A; Martínez-Barnetche J; Rodríguez MH; Ovilla-Muñoz M; Pérez F; Hernandez-Avila JE; Sandoval MA; Rodríguez Mdel C; Villarreal-Treviño C
    Infect Genet Evol; 2010 Jul; 10(5):645-54. PubMed ID: 20363376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.
    Sattabongkot J; Tsuboi T; Hisaeda H; Tachibana M; Suwanabun N; Rungruang T; Cao YM; Stowers AW; Sirichaisinthop J; Coleman RE; Torii M
    Am J Trop Med Hyg; 2003 Nov; 69(5):536-41. PubMed ID: 14695092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism.
    Hisaeda H; Collins WE; Saul A; Stowers AW
    Vaccine; 2001 Dec; 20(5-6):763-70. PubMed ID: 11738740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.
    Kongkasuriyachai D; Bartels-Andrews L; Stowers A; Collins WE; Sullivan J; Sattabongkot J; Torii M; Tsuboi T; Kumar N
    Vaccine; 2004 Aug; 22(23-24):3205-13. PubMed ID: 15297075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rapid genotyping method for the vivax malaria transmission-blocking vaccine candidates, Pvs25 and Pvs28.
    Tsuboi T; Kaneko O; Cao YM; Tachibana M; Yoshihiro Y; Nagao T; Kanbara H; Torii M
    Parasitol Int; 2004 Sep; 53(3):211-6. PubMed ID: 15468527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenic repertoire of Plasmodium vivax transmission-blocking vaccine candidates from the Indian subcontinent.
    Prajapati SK; Joshi H; Dua VK
    Malar J; 2011 May; 10():111. PubMed ID: 21535892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited sequence polymorphisms of four transmission-blocking vaccine candidate antigens in Plasmodium vivax Korean isolates.
    Kang JM; Ju HL; Moon SU; Cho PY; Bahk YY; Sohn WM; Park YK; Cha SH; Kim TS; Na BK
    Malar J; 2013 Apr; 12():144. PubMed ID: 23631662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence polymorphisms of Plasmodium vivax ookinete surface proteins (Pvs25 and Pvs28) from clinical isolates in Korea.
    Han ET; Lee WJ; Sattabongkot J; Jang JW; Nam MH; An SS; Suh I; Lim CS
    Trop Med Int Health; 2010 Sep; 15(9):1072-6. PubMed ID: 20545923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
    Tachibana M; Suwanabun N; Kaneko O; Iriko H; Otsuki H; Sattabongkot J; Kaneko A; Herrera S; Torii M; Tsuboi T
    Vaccine; 2015 Apr; 33(16):1901-8. PubMed ID: 25765968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transmission-blocking vaccine of vivax malaria.
    Tsuboi T; Tachibana M; Kaneko O; Torii M
    Parasitol Int; 2003 Mar; 52(1):1-11. PubMed ID: 12543142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolution and diversity of a low complexity vaccine candidate, merozoite surface protein 9 (MSP-9), in Plasmodium vivax and closely related species.
    Chenet SM; Pacheco MA; Bacon DJ; Collins WE; Barnwell JW; Escalante AA
    Infect Genet Evol; 2013 Dec; 20():239-48. PubMed ID: 24044894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.
    Blagborough AM; Musiychuk K; Bi H; Jones RM; Chichester JA; Streatfield S; Sala KA; Zakutansky SE; Upton LM; Sinden RE; Brian I; Biswas S; Sattabonkot J; Yusibov V
    Vaccine; 2016 Jun; 34(28):3252-9. PubMed ID: 27177945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate.
    Tachibana M; Sato C; Otsuki H; Sattabongkot J; Kaneko O; Torii M; Tsuboi T
    Vaccine; 2012 Feb; 30(10):1807-12. PubMed ID: 22245309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.